Smallpox vaccination campaigns resulted in age-associated population cross-immunity against monkeypox virus.
J Gen Virol
; 105(6)2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38861287
ABSTRACT
Increased human-to-human transmission of monkeypox virus (MPXV) is cause for concern, and antibodies directed against vaccinia virus (VACV) are known to confer cross-protection against Mpox. We used 430 serum samples derived from the Scottish patient population to investigate antibody-mediated cross-neutralization against MPXV. By combining electrochemiluminescence immunoassays with live-virus neutralization assays, we show that people born when smallpox vaccination was routinely offered in the United Kingdom have increased levels of antibodies that cross-neutralize MPXV. Our results suggest that age is a risk factor of Mpox infection, and people born after 1971 are at higher risk of infection upon exposure.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Vacuna contra Viruela
/
Monkeypox virus
/
Mpox
/
Anticuerpos Neutralizantes
/
Anticuerpos Antivirales
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
/
Middle aged
País como asunto:
Europa
Idioma:
En
Año:
2024
Tipo del documento:
Article